Treatment of glomerulonephritis: Will we ever have options other than steroids and cytotoxics?

Kidney International

Volumn 67, Issue 5, 2005, Pages 1692-1703

  Javaid, Basit ^a   Quigg, Richard J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Biological response modifiers; Glomerulonephritis; Immune response; Therapy

Indexed keywords

15 DEOXYSPERGUALIN; 2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; ABETIMUS; ALICAFORSEN; AZATHIOPRINE; BG 9588; CD40 LIGAND MONOCLONAL ANTIBODY; CELL ADHESION MOLECULE; CELL CYCLE PROTEIN; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DOUBLE STRANDED DNA; ECLUIZUMAB; EFALIZUMAB; ETANERCEPT; FINGOLIMOD; GLUCOCORTICOID; IMATINIB; IMMUNOGLOBULIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1; LEFLUNOMIDE; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3E10; MONOCLONAL ANTIBODY IDEC 131; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLATELET DERIVED GROWTH FACTOR; PROTEIN INHIBITOR; RAPAMYCIN; RECEPTOR ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT CTLA4; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; ROSCOVITINE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CELL PROLIFERATION; CLINICAL TRIAL; COMPLEMENT SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; GLOMERULONEPHRITIS; HEMATURIA; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; REVIEW; RHEUMATOID ARTHRITIS; STEM CELL TRANSPLANTATION; THROMBOEMBOLISM;

EID: 17744393464     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00266.x     Document Type: Article

References (141)

1. STRATTA P, CANAVESE C, SANDRI L, et al: The concept of "glomerulonephritis." The fascinating history of evolution and emergence of a specialist's nosology focus on Italy and Torino. Am J Nephrol 19:83-91, 1999
2. COUSER WG: Glomerulonephritis. Lancet 353:1509-1515, 1999
3. U.S. RENAL DATA SYSTEM: Incidence and prevalence of ESRD, in USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, 2003, pp 47-60
4. COGGINS CH: Four plus: The management of nephrosis. N Engl J Med 295:783-784, 1976
5. ADDIS T: Glomerular Nephritis: Diagnosis and Treatment, New York, The Macmillan Company, 1949
6. LUETSCHER JA, DEMING Q: Treatment of nephrosis with cortisone. J Clin Invest 29:1576-1587, 1950
7. CHASIS H, GOLDRING W, BALDWIN DS: Effect of febrile plasma, typhoid vaccine and nitrogen mustard on renal manifestations of human glomerulonephritis. Proc Soc Exp Biol Med 71:565-567, 1949
8. TAYLOR R, CORCORAN A, PAGE I: Treatment of the nephrotic syndrome with nitrogen mustard. J Lab Clin Med 36:996-997, 1950
9. BIALESTOCK D: Further investigations into aetiology of glomerulonephritis. Med J Aust 1:835-838, 1953
10. SIMONSEN M: Studies on the pathogenesis of experimental glomerulonephritis. Acta Pathol Microbiol Scand 32:85-108, 1953
11. DIXON FJ, WILSON CB: The development of immunopathologic investigation of kidney disease. Am J Kidney Dis 16:574-578, 1990
12. RILEY C, DAVIS R: Childhood nephrosis. Pediatr Clin North Am 6:893-910, 1955
13. SHEARN MA: Mercaptopurine in the treatment of steroid-resistant nephrotic syndrome. N Engl J Med 273:943-947, 1965
14. WHITE RH, CAMERON JS, TROUNCE JR: Immunosuppressive therapy in steroid-resistant proliferative glomerulonephritis accompanied by the nephrotic syndrome. Br Med J 2:853-860, 1966
15. GRUPE WE, HEYMANN W: Cytotoxic drugs in steroid-resistant renal disease. Alkylating and antimetabolic agents in the treatment of nephrotic syndrome, lupus nephritis, chronic glomerulonephritis, and purpura nephritis in children. Am J Dis Child 112:448-458, 1966
16. ADAMS DA, GORDON A, MAXWELL MH: Azathioprine treatment of immunological renal disease. JAMA 199:459-463, 1967
17. MUKHERJEE AP: Combined prednisolone, azathioprine, and cyclophosphamide treatment for persistent proliferative glomerulonephritis in adults. Lancet 2:1350-1353, 1971
18. HEJAILI FF, MOIST LM, CLARK WF: Treatment of lupus nephritis. Drugs 63:257-274, 2003
19. KUIPER-GEERTSMA DG, DERKSEN RH: Newer drugs for the treatment of lupus nephritis. Drugs 63:167-180, 2003
20. CHAN TM, LI FK, TANG CS, et al: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156-1162, 2000
21. CONTRERAS G, PARDO V, LECLERCQ B, et al: Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971-980, 2004
22. RUSSELL PJ, HICKS JD, BURNET FM: Cyclophosphamide treatment of kidney disease in (NZB x NZW) F1 mice. Lancet 1:1280-1284, 1966
23. GELFAND MC, STEINBERG AD, NAGLE R, KNEPSHIELD JH: Therapeutic studies in NZB-W mice. I. Synergy of azathioprine, cyclophosphamide and methylprednisolone in combination. Arthritis Rheum 15:239-246, 1972
24. CORNA D, MORIGI M, FACCHINETTI D, et al: Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 51:1583-1589, 1997
25. LEANDRO MJ, EDWARDS JC, CAMBRIDGE G, et al: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46:2673-2677, 2002
26. SPECKS U, FERVENZA FC, MCDONALD TJ, HOGAN MC: Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44:2836-2840, 2001
27. LOONEY RJ: Treating human autoimmune disease by depleting B cells. Ann Rheum Dis 61:863-866, 2002
28. LEFKOWITH JB, GILKESON GS: Nephritogenic autoantibodies in lupus. Current concepts and continuing controversies. Arthritis Rheum 39:894-903, 1996
29. JONES DS, BARSTAD PA, FEILD MJ, et al: Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J Med Chem 38:2138-2144, 1995
30. ALARCON-SEGOVIA D, TUMLIN JA, FURIE RA, et al: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 48:442-454, 2003
31. SOLSKY MA, WALLACE DJ: New therapies in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 16:293-312, 2002
32. BORZA DB, HUDSON BG: Molecular characterization of the target antigens of anti-glomerular basement membrane antibody disease. Springer Semin Immunopathol 24:345-361, 2003
33. KALLURI R, DANOFF TM, OKADA H, NEILSON EG: Susceptibility to anti-glomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice. J Clin Invest 100:2263-2275, 1997
34. REYNOLDS J, PUSEY CD: Oral administration of glomerular basement membrane prevents the development of experimental autoimmune glomerulonephritis in the WKY rat. J Am Soc Nephrol 12:61-70, 2001
35. BORZA DB, NEILSON EG, HUDSON BG: Pathogenesis of Goodpasture syndrome: A molecular perspective. Semin Nephrol 23:522-531, 2003
36. SALOMON B, BLUESTONE JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19:225-252, 2001
37. FRAUWIRTH KA, THOMPSON CB: Activation and inhibition of lymphocytes by costimulation. J Clin Invest 109:295-299, 2002
38. BIANCONE L, DEAMBROSIS I, CAMUSSI G: Lymphocyte costimulatory receptors in renal disease and transplantation. J Nephrol 15:7-16, 2002
39. DAIKH DI, WOFSY D: Treatment of autoimmunity by inhibition of T cell costimulation. Adv Exp Med Biol 490:113-117, 2001
40. BOUMPAS DT, FURIE R, MANZI S, et al: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48:719-727, 2003
41. KAWAI T, ANDREWS D, COLVIN RB, et al: Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 6:114, 2000
42. KALUNIAN KC, DAVIS JC, JR., MERRILL JT, et al: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:3251-3258, 2002
43. MORELAND LW, ALTEN R, VAN DEN BF, et al: Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46:1470-1479, 2002
44. KREMER JM, WESTHOVENS R, LEON M, et al: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907-1915, 2003
45. TAKIGUCHI M, MURAKAMI M, NAKAGAWA I, et al: Blockade of CD28/CTLA4-B7 pathway prevented autoantibody-related diseases but not lung disease in MRL/lpr mice. Lab Invest 79:317-326, 1999
46. KITCHING AR, HUANG XR, RUTH AJ, et al: Effects of CTLA4-Fc on glomerular injury in humorally-mediated glomerulonephritis in BALB/c mice. Clin Exp Immunol 128:429-435, 2002
47. KIRK AD, TADAKI DK, CELNIKER A, et al: Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 72:377-384, 2001
48. HAUSEN B, KLUPP J, CHRISTIANS U, et al: Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys. Transplantation 72:1128-1137, 2001
49. ARUFFO A, HOLLENBAUGH D: Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease. Curr Opin Immunol 13:683-686, 2001
50. YELLIN MJ, D'AGATI V, PARKINSON G, et al: Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 40:124-134, 1997
51. RUTH AJ, KITCHING AR, SEMPLE TJ, et al: Intrinsic renal cell expression of CD40 directs Th1 effectors inducing experimental crescentic glomerulonephritis. J Am Soc Nephrol 14:2813-2822.
52. NIEMANN-MASANEK U, MUELLER A, YARD BA, et al: B7-1 (CD80) and B7-2 (CD 86) expression in human tubular epithelial cells in vivo and in vitro. Nephron 92:542-556, 2002
53. GRAMMER AC, SLOTA R, FISCHER R, et al: Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 112:1506-1520, 2003
54. BOOTH AD, FIRTH JD, JAYNE DR: Immunotherapy for autoimmune and inflammatory renal diseases. Expert Opin Biol Ther 3:487-500, 2003
55. FINCK BK, LINSLEY PS, WOFSY D: Treatment of murine lupus with CTLA4Ig. Science 265:1225-1227, 1994
56. DIAMOND B, BLUESTONE J, WOFSY D: The immune tolerance network and rheumatic disease: Immune tolerance comes to the clinic. Arthritis Rheum 44:1730-1735, 2001
57. WEISBART RH, NORITAKE DT, WONG AL, et al: A conserved anti-DNA antibody idiotype associated with nephritis in murine and human systemic lupus erythematosus. J Immunol 144:2653-2658, 1990
58. SPERTINI F, LEIMGRUBER A, MOREL B, et al: Idiotypic vaccination with a murine anti-dsDNA antibody: Phase I study in patients with nonactive systemic lupus erythematosus with nephritis. J Rheumatol 26:2602-2608, 1999
59. ILLEI GG, CZIRJAK L: Novel approaches in the treatment of lupus nephritis. Expert Opin Investig Drugs 10:1117-1130, 2001
60. FOSTER MH, CIZMAN B, MADAIO MP: Biology of disease. Nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origins. Lab Invest 69:494-507, 1993
61. WEISMAN MH, BLUESTEIN HG, BERNER CM, DE HAAN HA: Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 24:314-318, 1997
62. MACANOVIC M, SINICROPI D, SHAK S, et al: The treatment of systemic lupus erythematosus (SLE) in NZB/WF1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 106:243-252, 1996
63. DAVIS JC, JR., MANZI S, YARBORO C, et al: Recombinant human DNase I (rhDNase) in patients with lupus nephritis. Lupus 8:68-76, 1999
64. KNEZEVIC-MARAMICA I, KRUSKALL MS: Intravenous immune globulins: An update for clinicians. Transfusion 43:1460-1480, 2003
65. MADAIO MP, HARRINGTON JT: The diagnosis of glomerular diseases: Acute glomerulonephritis and the nephrotic syndrome. Arch Intern Med 161:25-34, 2001
66. QUIGG RJ: Role of complement and complement regulatory proteins in glomerulonephritis. Springer Sem Immunopathol 24:412-428, 2002
67. COUSER WG: Complement inhibitors and glomerulonephritis: Are we there yet? J Am Soc Nephrol 14:815-818, 2003
68. WALPORT MJ: Advances in immunology: Complement (first of two parts). N Engl J Med 344:1058-1066, 2001
69. BOACKLE SA, HOLERS VM: Role of complement in the development of autoimmunity. Curr Dir Autoimmun 6:154-168, 2003
70. KERJASCHKI D, NEALE TJ: Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 7:2518-2526, 1996
71. WANG Y, HU Q, MADRI JA, et al: Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 93:8563-8568, 1996
72. CYBULSKY AV, FOSTER MH, QUIGG RJ, SALANT DJ: Immunologic mechanisms of glomerular disease, in The Kidney: Physiology and Pathophysiology, 3rd ed., edited by Seldin DW, Giebisch G, Philadelphia, Lippincott-Raven, 2000, pp 2645-2697
73. FLOEGE J, EITNER F, VAN ROEYEN C, OSTENDORF T: PDGF-D and renal disease: Yet another one of those growth factors? J Am Soc Nephrol 14:2690-2691, 2003
74. JOHNSON RJ, RAINES EW, FLOEGE J, et al: Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet- derived growth factor. J Exp Med 175:1413-1416, 1992
75. ROSKOSKI R, JR.: STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 309:709-717, 2003
76. GILBERT RE, KELLY DJ, MCKAY T, et al: PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59:1324-1332, 2001
77. FLOEGE J, OSTENDORF T, WOLF G: Growth factors and cytokines, chap. 20, in Immunologic Renal Diseases, 2nd ed., edited by Neilson EG, Couser WG, Philadelphia, Lippincott-Raven, 2001, pp 415-463
78. CUNNINGHAM PN, DYANOV HM, PARK P, et al: Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 168:5817-5823, 2002
79. CRISCIONE LG, ST CLAIR EW: Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 14:204-211, 2002
80. MULLIGAN MS, JOHNSON KJ, TODD RF III, et al: Requirements for leukocyte adhesion molecules in nephrotoxic nephritis. J Clin Invest 91:577-587, 1993
81. LAMPRECHT P, VOSWINKEL J, LILIENTHAL T, et al: Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 41:1303-1307, 2002
82. BOOTH A, HARPER L, HAMMAD T, et al: Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15:717-721, 2004
83. WEGENER'S GRANULOMATOSIS ETANERCEPT TRIAL (WGET) RESEARCH GROUP: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352:351-361, 2005
84. COHEN SB, STRAND V, AGUILAR D, OFMAN JJ: Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy. Rheumatology, 43:704-711, 2004
85. TESCH GH, LAN HY, ATKINS RC, NIKOLIC-PATERSON DJ: Role of interleukin-1 in mesangial cell proliferation and matrix deposition in experimental mesangioproliferative nephritis. Am J Pathol 151:141-150, 1997
86. TANG WW, FENG L, VANNICE JL, WILSON CB: Interleukin-1 receptor antagonist ameliorates experimental anti-glomerular basement membrane antibody-associated glomerulonephritis. J Clin Invest 93:273-279, 1994
87. LAN HY, NIKOLIC-PATERSON DJ, ZARAMA M, et al: Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. Kidney Int 43:479-485, 1993
88. KIBERD BA, STADNYK AW: Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule? Immunopharmacology 30:131-137, 1995
89. COHEN S, HURD E, CUSH J, et al: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:614-624, 2002
90. NIEMIR ZI, ONDRACEK M, DWORACKI G, et al: In situ upregulation of IL-10 reflects the activity of human glomerulonephritides. Am J Kidney Dis 32:80-92, 1998
91. HOUSSIAU FA, LEFEBVRE C, VANDEN BERGHE M, et al: Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4:393-395, 1995
92. ISHIDA H, MUCHAMUEL T, SAKAGUCHI S, et al: Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 179:305-310, 1994
93. LLORENTE L, RICHAUD-PATIN Y, GARCIA-PADILLA C, et al: Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43:1790-1800, 2000
94. CHADBAN SJ, TESCH GH, LAN HY, et al: Effect of interleukin-10 treatment on crescentic glomerulonephritis in rats. Kidney Int 51:1809-1817, 1997
95. HUANG XR, KITCHING AR, TIPPING PG, HOLDSWORTH SR: Interleukin-10 inhibits macrophage-induced glomerular injury. J Am Soc Nephrol 11:262-269, 2000
96. BAUD L, FOUQUERAY B, BELLOCQ A: Cytokines and hormones with anti-inflammatory effects: New tools for therapeutic intervention. Curr Opin Nephrol Hypertens 10:49-54, 2001
97. TIPPING PG, HOLDSWORTH SR: T cells in glomerulonephritis. Springer Semin Immunopathol 24:377-393, 2003
98. KUNKEL SL, GODESSART N: Chemokines in autoimmunity: From pathology to therapeutics. Autoimmun Rev 1:313-320, 2002
99. KELLEY VR, ROVIN BH: Chemokines: Therapeutic targets for autoimmune and inflammatory renal disease. Springer Semin Immunopathol 24:411-421, 2003
100. ANDERS HJ, VIELHAUER V, SCHLONDORFF D: Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 63:401-415, 2003
101. ZOJA C, CORNA D, BENEDETTI G, et al: Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int 53:726-734, 1998
102. TESCH GH, MAIFERT S, SCHWARTING A, et al: Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 190:1813-1824, 1999
103. VIGANO G, GOTTI E, CASIRAGHI F: Bindarit reduces urinary albumin excretion and urinary interleukin-6 in patients with proliferative lupus nephritis [abstract]. J Am Soc Nephrol 6:434, 1995
104. ANDERS HJ, FRINK M, LINDE Y, et al: CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol 170:5658-5666, 2003
105. ROSENKRANZ AR, MAYADAS TN: Leukocyte-endothelial cell interactions - Lessons from knockout mice. Exp Nephrol 7:125-136, 1999
106. ADLER S, BRADY HR: Cell adhesion molecules and the glomerulopathies. Am J Med 107:371-386, 1999
107. CLARKSON MR, BRADY HR: Leukocyte adhesion, chap. 25, in Immunologic Renal Diseases, 2nd ed., edited by Neilson EG, Couser WG, Philadelphia, Lippincott Williams & Wilkins, 2001, pp 551-578
108. ALLEN AR, MCHALE J, SMITH J, et al: Endothelial expression of VCAM-1 in experimental crescentic nephritis and effect of antibodies to very late antigen-4 or VCAM-1 on glomerular injury. J Immunol 162:5519-5527, 1999
109. KHAN SB, ALLEN AR, BHANGAL G, et al: Blocking VLA-4 prevents progression of experimental crescentic glomerulonephritis. Nephron Exp Nephrol 95:e100-e110, 2003
110. MILLER DH, KHAN OA, SHEREMATA WA, et al: A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15-23, 2003
111. GHOSH S, GOLDIN E, GORDON FH, et al: Natalizumab for active Crohn's disease. N Engl J Med 348:24-32, 2003
112. LOCKWOOD CM, ELLIOTT JD, BRETTMAN L, et al: Anti-adhesion molecule therapy as an interventional strategy for autoimmune inflammation. Clin Immunol 93:93-106, 1999
113. VINCENTI F: New monoclonal antibodies in renal transplantation. Minerva Urol Nefrol 55:57-66, 2003
114. STERN RS: A promising step forward in psoriasis therapy. JAMA 290:3133-3135, 2003
115. SALMELA K, WRAMNER L, EKBERG H, et al: A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: A report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation 67:729-736, 1999
116. ENLIMOMAB ACUTE STROKE TRIAL INVESTIGATORS: Use of anti-ICAM-1 therapy in ischemic stroke: Results of the Enlimomab Acute Stroke Trial. Neurology 57:1428-1434, 2001
117. VUORTE J, LINDSBERG PJ, KASTE M, et al: Anti-ICAM-1 monoclonal antibody R6.5 (enlimomab) promotes activation of neutrophils in whole blood. J Immunol 162:2353-2357, 1999
118. YACYSHYN BR, CHEY WY, GOFF J, et al: Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 51:30-36, 2002
119. MAKSYMOWYCH WP, BLACKBURN WD, JR., TAMI JA, SHANAHAN WR, JR.: A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis. J Rheumatol 29:447-453, 2002
120. HENRY SP, BEATTIE G, YEH G, et al: Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol 2:1657-1666, 2002
121. MOELLER MJ, SOOFI A, HARTMANN I, et al: Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis. J Am Soc Nephrol 15:61-67, 2004
122. GRIFFIN SV, PICHLER R, WADA T, et al: The role of cell cycle proteins in glomerular disease. Semin Nephrol 23:569-582, 2003
123. KUROGI Y: Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med Res Rev 23:15-31, 2003
124. GUAN Y, BREYER MD: Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int 60:14-30, 2001
125. PIPPIN JW, QU Q, MEIJER L, SHANKLAND SJ: Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. J Clin Invest 100:2512-2520, 1997
126. GHERARDI D, D'AGATI VD, CHU TT, et al: Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J Am Soc Nephrol 15:1212-1222, 2004
127. VERMEULEN K, VAN BOCKSTAELE DR, BERNEMAN ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36:131-149, 2003
128. SENDEROWICZ AM: Small-molecule cyclin-dependent kinase modulators. Oncogene 22:6609-6620, 2003
129. DRAGNEV KH, PETTY WJ, DMITROVSKY E: Retinoid targets in cancer therapy and chemoprevention. Cancer Biol Ther 2:S150-S156, 2003
130. KINOSHITA K, YOO BS, NOZAKI Y, et al: Retinoic acid reduces autoimmune renal injury and increases survival in NZB/W F(1) mice. J Immunol 170:5793-5798, 2003
131. WAGNER J, DECHOW C, MORATH C, et al: Retinoic acid reduces glomerular injury in a rat model of glomerular damage. J Am Soc Nephrol 11:1479-1487, 2000
132. OSETO S, MORIYAMA T, KAWADA N, et al: Therapeutic effect of all-trans retinoic acid on rats with anti-GBM antibody glomerulonephritis. Kidney Int 64:1241-1252, 2003
133. FOGO AB, KON V: Pathophysiology of progressive renal disease, chap. 4, in Immunologic Renal Diseases, 2nd ed., edited by Neilson EG, Couser WG, Philadelphia, Lippincott Williams & Wilkins, 2001, pp 55-72
134. LIU Y: Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15:1-12, 2004
135. STRUTZ F, NEILSON EG: New insights into mechanisms of fibrosis in immune renal injury. Springer Semin Immunopathol 24:459-476, 2003
136. KALLURI R, NEILSON EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776-1784, 2003
137. FOGO AB: Renal fibrosis: Not just PAI-1 in the sky. J Clin Invest 112:326-328, 2003
138. ZEISBERG M, HANAI J, SUGIMOTO H, et al: BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9:964-968, 2003
139. YANG J, DAI C, LIU Y: Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol 163:621-632, 2003
140. YANG J, LIU Y: Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 13:96-107, 2002
141. HUANG Y, HARAGUCHI M, LAWRENCE DA, et al: A mutant, non-inhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 112:379-388, 2003